Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.
暂无分享,去创建一个
Mitsugu Sekimoto | Hiroaki Nagano | Morito Monden | Masayoshi Yasui | Chew Yee Ngan | M. Monden | H. Nagano | C. Ngan | M. Sekimoto | N. Matsuura | Hirofumi Yamamoto | M. Sakon | S. Nakamori | Shoji Nakamori | Masato Sakon | Xundi Xu | Hirofumi Yamamoto | Hiroki Fukunaga | Tetsushi Morita | Minoru Ogawa | Nariaki Matsuura | M. Yasui | Xundi Xu | H. Fukunaga | T. Morita | M. Ogawa
[1] M. Kojiro,et al. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. , 2008, Liver.
[2] C. Wilcox,et al. Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs. , 2001, Cancer research.
[3] Y. Doki,et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus , 2001, British Journal of Cancer.
[4] C. Cerni,et al. Cdc25A phosphatase suppresses apoptosis induced by serum deprivation , 2001, Oncogene.
[5] H. Kiyokawa,et al. The Cell Cycle-Regulatory CDC25A Phosphatase Inhibits Apoptosis Signal-Regulating Kinase 1 , 2001, Molecular and Cellular Biology.
[6] G. Ercolani,et al. Improved Results of Liver Resection for Hepatocellular Carcinoma on Cirrhosis Give the Procedure Added Value , 2001, Annals of surgery.
[7] N. Nagasue,et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis , 2001, The British journal of surgery.
[8] G. Powis,et al. Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. , 2001, Journal of medicinal chemistry.
[9] J. Slingerland,et al. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells , 2000, Oncogene.
[10] V Torri,et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. , 2000, Anticancer research.
[11] M. Loda,et al. Role of the Cdc25A phosphatase in human breast cancer. , 2000, The Journal of clinical investigation.
[12] H. Naiki,et al. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. , 2000, Annals of surgery.
[13] M Monden,et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. , 2000, Cancer research.
[14] H. Hibshoosh,et al. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice , 1999, Oncogene.
[15] Ingrid,et al. Ectopic Expression of Cdc25A Accelerates the G1/S Transition and Leads to Premature Activation of Cyclin E- and Cyclin A-Dependent Kinases , 1999, Molecular and Cellular Biology.
[16] S. Tsai,et al. Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B , 1999, Oncogene.
[17] M. Monden,et al. Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.
[18] R. Prywes,et al. Serum-Induced Expression of the cdc25AGene by Relief of E2F-Mediated Repression , 1999, Molecular and Cellular Biology.
[19] L. Mao,et al. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. , 1998, Cancer research.
[20] M. Buendia,et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] T. Moyana,et al. Elevated expression of the cdc25A protein phosphatase in colon cancer. , 1998, Experimental cell research.
[22] E. Montserrat,et al. cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. , 1998, Cancer Research.
[23] Jeng-Jong Hwang,et al. Ki‐67 expression as a prognostic marker in patients with hepatocellular carcinoma , 1998, Journal of gastroenterology and hepatology.
[24] H. Yokozaki,et al. Overexpression of Cyclin‐dependent Kinase‐activating CDC25B Phosphatase in Human Gastric Carcinomas , 1997, Japanese journal of cancer research : Gann.
[25] Xiao-Feng Sun,et al. Ki‐67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[26] R. Maestro,et al. Overexpression of CDC25A and CDC25B in head and neck cancers. , 1997, Cancer research.
[27] J. Massagué,et al. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15 , 1997, Nature.
[28] S. Hirohashi,et al. Reduced p21WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas , 1997, Hepatology.
[29] D. Huhn,et al. Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). , 1996, Nucleic acids research.
[30] S. Hirohashi,et al. Inactivation of p16INK4 in hepatocellular carcinoma , 1996, Hepatology.
[31] D. Beach,et al. Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.
[32] N. Hayward,et al. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. , 1996, Journal of cell science.
[33] O. Nakashima,et al. Pathology of early hepatocellular carcinoma: progression from early to advanced. , 1996, Seminars in surgical oncology.
[34] M. Loda,et al. CDC25 phosphatases as potential human oncogenes. , 1995, Science.
[35] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[36] C. Sherr. G1 phase progression: Cycling on cue , 1994, Cell.
[37] S. Fan,et al. Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma , 1994, Cancer.
[38] H Nojima,et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. , 1994, The EMBO journal.
[39] N. Nishida,et al. Molecular aspects of hepatocarcinogenesis and their clinical implications - review. , 1994, International journal of oncology.
[40] M. Tsuneyoshi,et al. Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia , 1993, Cancer.
[41] C. J. Chen,et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.
[42] T. Bauer,et al. Ki‐67‐determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: A multivariate analysis , 1992, Cancer.
[43] P. Lipponen,et al. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. , 1992, Anticancer research.
[44] H. Piwnica-Worms,et al. p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[45] D. Beach,et al. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins , 1991, Cell.
[46] S. Hirohashi,et al. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.
[47] A Nagata,et al. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. , 1991, The New biologist.
[48] K. Sadhu,et al. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[49] G. Peters,et al. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.